These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28641700)

  • 1. [Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer].
    Luo D; Ma J; Zhang J; Zhao Y
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):415-420. PubMed ID: 28641700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current Status and Progress in Molecular Imaging of Non-small Cell Lung 
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and 
Treatment Tolerance Prediction].
    Dai D; Xu W; Wang Q; Li X; Zhu Y
    Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):852-856. PubMed ID: 29277186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
    Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
    Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC.
    Xiao Z; Song Y; Kai W; Sun X; Shen B
    Oncotarget; 2017 Jun; 8(25):40732-40740. PubMed ID: 28489575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
    J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
    Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
    Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
    Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
    Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
    Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
    Huang MJ; Lim KH; Tzen CY; Hsu HS; Yen Y; Huang BS
    Lung Cancer; 2005 Sep; 49(3):413-5. PubMed ID: 15913841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
    Giuliani J; Martelli S; Remo A; Bonetti A
    Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.
    Cheng Z; Shan F; Yang Y; Shi Y; Zhang Z
    BMC Med Imaging; 2017 Jan; 17(1):5. PubMed ID: 28068946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan.
    Guan J; Chen M; Xiao N; Li L; Zhang Y; Li Q; Yang M; Liu L; Chen L
    Med Oncol; 2016 Jan; 33(1):1. PubMed ID: 26589606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
    Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
    Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.